ema tirzepatide Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026 EMA warns of rise in

It was approved by the FDA in 2020 for managing excess weight and is considered one of the few prescription-only anti-obesity medications

Focus on eating enough and choosing balanced meals that support energy, recovery, and milk production rather than restriction

Slowing an infusion may help some rate-related symptomsbut does not diagnose them Chest symptoms, low blood pressure, breathing difficulty, severe pain, or neurologic symptoms require assessment rather than automatic continuation at a slower rate

35-54 Age Group Emerges as Key Target Demographic The 35-54 age group held a 30.6% share in 2024 and is forecast to reach 33% in 2025

What to Expect Without Insurance Understanding your options is important

The craving got quieter, and they were able to move on